The news reporters obtained a quote from the research, "Current mobilization regimens include cytokines such as G-CSF and/or chemotherapy. However not all patients mobilize enough HSC to proceed to transplant. The chemokine receptor CXCR4 and its ligand CXCL12 are an integral part of the mechanism of HSC retention in the bone marrow niche. The discovery of plerixafor, a selective inhibitor of CXCR4, has provided a new additional means of mobilizing HSC for autologous transplantation. Plerixafor consists of two cyclam rings with a phenylenebis(methylene) linker. It inhibits CXCL12 binding to CXCR4 and subsequent downstream events including chemotaxis. The molecular interactions of plerixafor have been defined indicating a unique binding mode to CXCR4. Plerixafor rapidly mobilizes HSC within hours compared with the multi-day treatment required by G-CSF in mouse, dog and non-human primate. The mobilized cells once transplanted are capable of timely and endurable engraftment."
According to the news reporters, the research concluded: "Additionally CXCR4 has been implicated in the pathology of HIV, inflammatory disease and cancer and the pharmacology of plerixafor in various disease models is described."
For more information on this research see: Physiology and Pharmacology of Plerixafor. Transfusion Medicine and Hemotherapy, 2013;40(4):237-245. Transfusion Medicine and Hemotherapy can be contacted at: Karger, Allschwilerstrasse 10, Ch-4009
Our news correspondents report that additional information may be obtained by contacting
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- Dell Offers Undisclosed Number of Employee Buyouts
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Authorities Close to Deal with JPMorgan Chase over Madoff Response
- Apple Activates Customer-Tracking iBeacon
- 2013 Tech Gift Guide: iPad Mini Still Hot; Chromecast a Great Low-Cost Option
- A Biography of Jonathan Ive, Apple's Creative Chief
- It's No Yolk: Food-tech Startups Take Aim at Replacing Eggs
- U.S. Stocks Rise on Sysco Acquisition